Patients with stage II , III , or IVA esophageal cancer were randomly allocated to either @ cycles of ICT ( oxaliplatin @ mg/m ( @ ) on day @ and S@ at @ mg/m ( @ ) twice daily on days @-@ , every @ weeks ) followed by concurrent chemoradiotherapy ( CCRT ) ( @ Gy , @ Gy/d with oxaliplatin @ mg/m ( @ ) on days @ and @ and S@ @ mg/m ( @ ) twice daily , @ days per week during radiation therapy ) and esophagectomy ( arm A ) , or the same CCRT followed by esophagectomy without ICT ( arm B ) .